Synthorx Raises $10M

San Diego-based Synthorx, a developer of protein therapeutics technology, said it has raised $10M in a Series B financing this morning. The funding was led by RA Capital Management, and also included Avalon Ventures and Correlation Ventures. RA Capital Management's Andrew Levin joins the company's board with the funding. Synthorx is focused on developing synthetic biology techniques for producing proteins that cannot be made through traditional methods. The company's technology is based on research from The Scripps Research Institute. More information »